Compare MWH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWH | IMVT |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.0B |
| IPO Year | N/A | 2019 |
| Metric | MWH | IMVT |
|---|---|---|
| Price | $28.92 | $24.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $35.10 | $30.78 |
| AVG Volume (30 Days) | 658.9K | ★ 997.2K |
| Earning Date | 03-19-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.54 | N/A |
| Revenue Next Year | $14.28 | N/A |
| P/E Ratio | $50.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.60 | $12.72 |
| 52 Week High | $33.00 | $29.25 |
| Indicator | MWH | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 42.84 |
| Support Level | $27.24 | $22.00 |
| Resistance Level | $30.66 | $24.63 |
| Average True Range (ATR) | 1.60 | 1.16 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 43.29 | 32.41 |
SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.